Canada Approves Roche's HPV Test as a First-line Cervical Cancer Screen | GenomeWeb

NEW YORK (GenomeWeb) – Roche announced after the close of the market on Tuesday that Health Canada approved the cobas 4800 HPV Test as a first-line primary screening test for cervical cancer in women at least 25 years old.

The announcement follows similar approval of the test by the US Food and Drug Administration in April.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.